van Geel R - Search Results

1

Validation of an analytical method using HPLC-MS/MS to quantify osimertinib in human plasma and supplementary stability results.

van Veelen A, van Geel R, de Beer Y, Dingemans AM, Stolk L, Ter Heine R, de Vries F, Croes S. van Veelen A, et al. Among authors: van geel r. Biomed Chromatogr. 2020 Apr;34(4):e4771. doi: 10.1002/bmc.4771. Epub 2020 Feb 3. Biomed Chromatogr. 2020. PMID: 31808583

2

Development and validation of an HPLC-MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run.

van Veelen A, van Geel R, Schoufs R, de Beer Y, Stolk LM, Hendriks LEL, Croes S. van Veelen A, et al. Among authors: van geel r. Biomed Chromatogr. 2021 Dec;35(12):e5224. doi: 10.1002/bmc.5224. Epub 2021 Aug 31. Biomed Chromatogr. 2021. PMID: 34363425

3

Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial.

van Veelen A, Gulikers J, Hendriks LEL, Dursun S, Ippel J, Smit EF, Dingemans AC, van Geel R, Croes S. van Veelen A, et al. Among authors: van geel r. Lung Cancer. 2022 Sep;171:97-102. doi: 10.1016/j.lungcan.2022.07.012. Epub 2022 Jul 25. Lung Cancer. 2022. PMID: 35933915 Free article. Clinical Trial.

4

Comment on "Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark".

van Veelen A, Nielen JTH, van Geel R, Croes S. van Veelen A, et al. Among authors: van geel r. J Am Acad Dermatol. 2021 Dec;85(6):e357. doi: 10.1016/j.jaad.2019.01.087. Epub 2019 Feb 13. J Am Acad Dermatol. 2021. PMID: 30771418 No abstract available.

5

Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors.

van Veelen A, Abtahi S, Souverein P, Driessen JHM, Klungel OH, Dingemans AC, van Geel R, de Vries F, Croes S. van Veelen A, et al. Among authors: van geel r. Cancer Epidemiol. 2022 Jun;78:102149. doi: 10.1016/j.canep.2022.102149. Epub 2022 Apr 13. Cancer Epidemiol. 2022. PMID: 35429893 Free article. Clinical Trial.

6

Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.

van Brummelen EMJ, Huijberts S, van Herpen C, Desar I, Opdam F, van Geel R, Marchetti S, Steeghs N, Monkhorst K, Thijssen B, Rosing H, Huitema A, Beijnen J, Bernards R, Schellens J. van Brummelen EMJ, et al. Among authors: van geel r, van herpen c. Oncologist. 2021 Apr;26(4):290-e545. doi: 10.1002/onco.13631. Epub 2020 Dec 29. Oncologist. 2021. PMID: 33296125 Free PMC article. Clinical Trial.

7

Cannabinoid consumption among cancer patients receiving systemic anti-cancer treatment in the Netherlands.

Oelen Y, Revenberg S, de Vos-Geelen J, van Geel R, Schoenmaekers J, van den Beuken-Everdingen M, Valkenburg-van Iersel L. Oelen Y, et al. Among authors: van geel r. J Cancer Res Clin Oncol. 2023 May;149(5):1863-1872. doi: 10.1007/s00432-022-04085-z. Epub 2022 Jul 2. J Cancer Res Clin Oncol. 2023. PMID: 35779108 Free PMC article.

8

Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer.

Huijberts SC, van Geel RM, Bernards R, Beijnen JH, Steeghs N. Huijberts SC, et al. Among authors: van geel rm. Future Oncol. 2020 Feb;16(6):161-173. doi: 10.2217/fon-2019-0748. Future Oncol. 2020. PMID: 32027186 Review.

9

Systematic Evaluation of Osimertinib Population Pharmacokinetic Models in a Cohort of Dutch Adults with Non-Small Cell Lung Cancer.

Westra N, Kruithof PD, Croes S, van Geel RMJM, Hendriks LEL, Touw DJ, Oude Munnink TH, Mian P. Westra N, et al. Among authors: van geel rmjm. Eur J Drug Metab Pharmacokinet. 2024 Jun 15. doi: 10.1007/s13318-024-00904-5. Online ahead of print. Eur J Drug Metab Pharmacokinet. 2024. PMID: 38878145

10

Proactive monitoring of drug-drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer.

Gulikers JL, Otten LS, Hendriks LEL, Winckers K, Henskens Y, Leentjens J, van den Heuvel MM, Ter Heine R, Croes S, Piet B, van Geel RMJM. Gulikers JL, et al. Among authors: van geel rmjm. Br J Cancer. 2024 Jun 11. doi: 10.1038/s41416-024-02744-1. Online ahead of print. Br J Cancer. 2024. PMID: 38862741

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

48 results

Search Page